We have shown that SIRT1 promotes acquisition of resistant BCR-ABL mutations in CML cells in association with its ability to stimulate aberrant NHEJ activity by deacetylating KU70 [5, 6]. The gene discussed is SIRT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.